30 closest matches · ranked by relevance
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Primary: Correlation of Tumor-informed CAPP-Seq ctDNA Analysis With Radiologic Tumor Assessments — 100; 66; 100; NA Percent Accuracy
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Non-Small Cell Lung Cancer
Primary: Number of Participants With High Grade (Grade 3, 4 and 5) Treatment Related Select Adverse Events — 1; 7; 0; 1 Participants
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 8.5 months
Non-small Cell Lung Cancer
Primary: Overall Survival — 12.55; 13.40 months — p=0.94896
Recurrent Non-Small Cell Lung Carcinoma · Stage IV Non-Small Cell Lung Cancer AJCC v7
Primary: Objective Response Rate — 10.8 percentage of participants
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Non-small Cell Lung Cancer
Primary: Intracranial Objective Response Rate — 6; 0; 5; 0 Participants
NSCLC Stage IV
Primary: Objective Response Rate (ORR) — 6 Participants
Non Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) During the Induction and Maintenance Therapy Periods — 5.6 months
Non-Small-Cell Lung Cancer
Primary: Percentage of Participants With a Tumor Response (Objective Tumor Response Rate) — 38.5 percentage of participants
Non-Small Cell Lung Cancer Stage IV
Primary: Progression Free Survival (PFS) — 2.53; 4.21 months — p=0.0068
Non Small Cell Lung Cancer
Primary: Overall Survival Time (OS) — 11.5; 9.9 Months — p=0.0120
Non-Small-Cell Lung Carcinoma
Primary: Progression-free Survival (PFS) — 5.45; 5.22 months — p=0.848
Lung Cancer · Metastatic Cancer
Primary: Number of Patients With Intracranial Response — 3 participants
Non-small Cell Lung Cancer (NSCLC) · Stage IV NSCLC · Metastatic NSCLC
Primary: Objective Response Rate — 0; 1 participants
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Non Small Cell Lung Cancer
Primary: Overall Survival Time (OS) — 11.3; 11.5 Months — p=0.9561
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) in the TC3 or IC3-WT Populations — 13.1; 20.2 Months — p=0.0106
Squamous NSCLC
Primary: PFS(Progression Free Survival) — 5.5; 4.9 months
NSCLC Stage IIIB · NSCLC Stage IV · EGFR Gene Mutation
Primary: Objective Response Rate (ORR) According to RECIST 1.1 — 39; 33 Participants
Non-small Cell Lung Cancer
Primary: Progression Free Survival (PFS) Rate as Per Investigator Local Review Measured Using RECIST 1.1 of Patients at Week 12 — 23.3; 20.0 Percentage of participants
Non-Squamous Cell Non-small Cell Lung Cancer
Primary: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint — 12.19; 9.36 Months — p=0.0015
Non-Small Cell Lung Cancer
Primary: Progression-free Survival — 2.2; 2.6 months — p=0.6873
Non Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 2.89; 2.76; 2.37; 1.54 months — p=0.756
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]) — 3.0; 4.3; 3.8; 4.8 percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: Overall Survival (OS) in the ITT (Non-squamous) Population — 376; 379 days — p=0.401
Advanced Non-small Cell Lung Cancer
Primary: Best Overall Response (BOR) — 2; 2; 9; 1 Participants
Squamous Non-small Cell Lung Cancer
Primary: Time on Treatment With Afatinib or Chemotherapy During Second Line (2L) Treatment — 7.3; 4.2 months
Carcinoma, Non-Small Cell Lung
Primary: Progression-Free Survival (PFS) — 8.0; 8.1; 7.1 months — p=0.3037